Capsaicin (capsaicinoids and capsinoids) trials recruiting now
5 registrations that name capsaicin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 5 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 5 registrations
RecruitingNCT07260656
Efficacy of a Topical Palmitated Formulation of Capsaicin (Capsadyn®) In the Treatment of Diabetic Neuropathic Foot Pain
Early phase 1
Carilion Clinic
About 80 people
Started Nov 26, 2025
In plain words An early phase 1 study of capsaicin in people 25 to 75, run by Carilion Clinic. It plans to enroll about 80 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 25 to 75. Conditions: Diabetic Neuropathies, Painful; Diabetic Foot; Diabetic Peripheral Neuropathy.
At least 3 toes per foot
Have otherwise intact feet.
Absence of any eczema, hyperkeratosis, scleroderma, or other dermatological conditions afflicting the area of Test Article administration that may interfere with absorption, particularly hyperhidrosis.
Must agree to apply the Test Article to painful areas of feet as directed by research personnel.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Capsaicin Palmitate; Placebo
Registered summary
The purpose of this research is to assess whether the use of a topical cream with an active ingredient can reduce the amount of foot pain experienced in participants who have been diagnosed with Diabetic Peripheral Neuropathy (DPN) with minimal side effects or discomfort from use.
Where, as registered
1 US site in 1 state.
RecruitingNCT05840562
Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy
Phase 3
Institut Cancerologie de l'Ouest
About 274 people
Started Oct 20, 2023
In plain words A Phase 3 study of capsaicin in people 18 and older, run by Institut Cancerologie de l'Ouest. It plans to enroll about 274 people at 11 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Chemotherapy-induced Peripheral Neuropathy.
Patient with CIPN manifested by painful symptoms such as numbness and / or tingling and / or burning pain in fingers / hands and toes / feet with a typical distribution in "gloves and socks" beginning after neurotoxic chemotherapy
Painful CIPN as expressed by the BPI-SF (average pain) as ≥ 4/10
CIPN persisting at least 1 month after completion of chemotherapy with taxanes and/or platinum salts and sensory CIPN grade ≥ 2 according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE v.5.0) grading scale
Stable doses in the 4 weeks before screening, of concomitant neuropathic pain medication (antiepileptic drugs)
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Capsaicin; Duloxetine
Registered summary
Chemotherapy induced peripheral neuropathy (CIPN) is a frequent and disabling complication of systemic chemotherapy, particularly with oxaliplatin or taxanes. The incidence of CIPN is variable but approximately 30-40% of patients treated with neurotoxic chemotherapy agents develop CIPN after long-term use of taxanes or oxaliplatin. This CIPN is essentially a sensory peripheral neuropathy with pain manifested by unpleasant symptoms such as numbness, tingling, and less frequently shooting/burning pain. The full summary is on the listing.
Where, as registered
No US site; France (11).
RecruitingNCT05983263
Analgesic Efficacy of Capsaicin 8% Patch (QUTENZA®) in Coccygodygnia
Observational
Nantes University Hospital
About 106 people
Started Nov 8, 2023
In plain words An observational study of capsaicin in people of any age, run by Nantes University Hospital. It plans to enroll about 106 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people of any age. Conditions: Coccyx Disorder.
Patients who received topical Capsaicin 8% patch therapy for the treatment of their coccygodygnia between August 2016 and August 2022
The exclusion criteria are on the listing.
What it tests, as registered
Capsaicin
Registered summary
A retrospective study over a period of 6 years to explore analgesic efficacy of 8% Capsaicin patch (QUTENZA®) in coccygodynic patients, as well as neuropathic predictive factors of therapeutic response.
Where, as registered
No US site; France (1).
RecruitingNCT07406971
Safety of Transmucosal Capsaicin Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke
Phase 2
Instituto Mexicano del Seguro Social
About 46 people
Started Sep 1, 2025
In plain words A Phase 2 study of capsaicin in people 18 and older, run by Instituto Mexicano del Seguro Social. It plans to enroll about 46 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Ischemic Stroke.
Age between 18 and 80 years.
National Institutes of Health Stroke Scale (NIHSS) score between 6 and 20 at screening.
Symptom onset within 24 hours prior to study intervention.
Pre-stroke modified Rankin Scale (mRS) score ≤1.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Capsaicin Transmucosal Oral Film; Placebo Transmucosal Oral Film
Registered summary
This study will evaluate the safety and tolerability of a dissolvable oral film containing a very small dose of capsaicin (the compound that produces the "hot" sensation in chili peppers) in adults with acute ischemic stroke. The film is designed to stimulate nerves in the mouth that may activate the sphenopalatine ganglion, a structure involved in regulating blood flow to the brain. The main purpose of this study is to determine whether the capsaicin film can be given safely to patients with acute ischemic stroke when started within 24 hours of symptom onset. The full summary is on the listing.
Where, as registered
No US site; Mexico (1).
RecruitingNCT07237022
The Role of TRP Channels in DPN
Observational
Universitaire Ziekenhuizen KU Leuven
About 20 people
Started Oct 8, 2025
In plain words An observational study of capsaicin in people 18 to 45, run by Universitaire Ziekenhuizen KU Leuven. It plans to enroll about 20 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45; healthy volunteers accepted. Conditions: Physiological Responses.
Subject is a white male or female ≥18 and ≤45 years of age
Subject is a non-smoker for at least 6 months prior to the start of the study
Subject has a body mass index (BMI) between 18-30 kg/m²
Subject is judged to be in good general health on the basis of medical history, physical examination and vital signs
1 more inclusion criterion and the exclusion criteria are on the listing.
The study aims to characterize the vascular response upon topical application of cinnamaldehyde, allyl isothiocyanate and capsaicin on feet skin in healthy volunteers. The vascular response will be characterized in terms of response over time, dose-response, inter-foot and inter-period reproducibility.